

# BMT Bio Marketing Diagnostics

BMT Diagnostics

[WWW.BMTDIAGNOSTICS.COM](http://WWW.BMTDIAGNOSTICS.COM)

BMT Diagnostics Ltd. (hereinafter "BMT" or the "Company") was founded in 2004 and has been active in developing, manufacturing and marketing rapid diagnostic tests (RDT) in Israel and internationally. Focused initially on introducing rapid diagnostic for POC, Health Maintenance Organizations (HMO), pharmacies, hospitals, laboratories - for self- and professional testing, BMT has led the adoption of RDT as a first-line screening tool by physicians and patients. This has created a new market opportunity, opening the door to additional tests that bridge the patient-physician chasm.

BMT has pioneered a first of its kind, simple-to-use, integrated device for Strep A testing under its Lab-On-Time™. BMT's Strep A RDT is being used by leading Israeli HMOs and directly marketed through Israeli pharmacies for professional use. Patients buy these tests at pharmacies and bring them to their family physicians for test performance. This marketing strategy has been successfully implemented since 2004.

BMT is in the process of developing additional swab-based tests as part of the Lab-On-Time™ platform, such as Strep B, Gonorrhea, and Chlamydia. Additionally, a prototype for an integrated blood sampling and analysis platform has been developed and successfully tested under laboratory conditions. This novel platform is targeting blood-based RDT for infectious diseases that have relatively simple regulatory routes, such as those for H. pylori, Syphilis, Malaria, Mycoplasma Pneumonia, Tuberculosis and Mononucleosis. These tests will initially target the POC, being offered for professional use only, but once proven as safe, simple to use and accurate, these tests will further aim at the home-testing market, selling through pharmacies and drug stores.

BMT has one international patent application covering its core swab-based integrated sampling and testing device platform, which is currently at National Phase. A second patent application for blood sampling and analysis was filed.

Lately we have added to our portfolio several RDT for Covid-19: IgM/IgG serological test cassette, Antigen test cassette and Combo COVID-19 Antigen, Influenza A + B cassette.

The blood serology tests were already validated in several countries and are already in use in multiple territories.

Currently we are working on a new innovative product with the support of Israeli Innovation Authority. This new product includes an application that can assist the authorities to record test results and communicate them to the patient.

BMT is looking for potential partners in key territories to distribute and market its products:

1. Primarily distributors of medical equipment, mainly of rapid diagnostic tests (RDT).
2. Procurement divisions at hospital and clinics.
3. Pharma chain stores.

